Literature DB >> 20044056

Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates.

Rolando Pajon1, Peter T Beernink, Lee H Harrison, Dan M Granoff.   

Abstract

Meningococcal factor H-binding protein (fHbp) is a promising vaccine candidate that elicits serum bactericidal antibodies in humans. Based on sequence variability of the entire protein, fHbp has been divided into three variant groups or two sub-families. We recently reported that the fHbp architecture was modular, consisting of five variable segments, each encoded by genes from one of two lineages. Based on combinations of segments from different lineages, all 70 known fHbp sequence variants could be classified into one of six modular groups. In this study, we analyzed sequences of 172 new fHbp variants that were available from public databases. All but three variants could be classified into one of the six previously described modular groups. Among systematically collected invasive group B isolates from the U.S. and Europe, modular group I overall was most common (60%) but group IV (natural chimeras) accounted for 23% of UK isolates and <1% of U.S. isolates (P<0.0001). Mouse antisera to recombinant fHbp from each of the modular groups showed modular group-specific bactericidal activity against strains with low fHbp expression but had broader activity against strains with higher fHbp expression. Thus both modular group and relative expression of fHbp affected strain susceptibility to anti-fHbp bactericidal activity. The results confirmed the modular architecture of fHbp and underscored its importance for the design of broadly protective group B vaccines in different regions. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20044056      PMCID: PMC2830318          DOI: 10.1016/j.vaccine.2009.12.027

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  33 in total

1.  MUSCLE: multiple sequence alignment with high accuracy and high throughput.

Authors:  Robert C Edgar
Journal:  Nucleic Acids Res       Date:  2004-03-19       Impact factor: 16.971

2.  Application of phylogenetic networks in evolutionary studies.

Authors:  Daniel H Huson; David Bryant
Journal:  Mol Biol Evol       Date:  2005-10-12       Impact factor: 16.240

3.  Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles.

Authors:  Germano Ferrari; Ignazio Garaguso; Jeannette Adu-Bobie; Francesco Doro; Anna Rita Taddei; Alessia Biolchi; Brunella Brunelli; Marzia Monica Giuliani; Mariagrazia Pizza; Nathalie Norais; Guido Grandi
Journal:  Proteomics       Date:  2006-03       Impact factor: 3.984

Review 4.  Review of meningococcal group B vaccines.

Authors:  Dan M Granoff
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

5.  Complete genome sequence of Neisseria meningitidis serogroup B strain MC58.

Authors:  H Tettelin; N J Saunders; J Heidelberg; A C Jeffries; K E Nelson; J A Eisen; K A Ketchum; D W Hood; J F Peden; R J Dodson; W C Nelson; M L Gwinn; R DeBoy; J D Peterson; E K Hickey; D H Haft; S L Salzberg; O White; R D Fleischmann; B A Dougherty; T Mason; A Ciecko; D S Parksey; E Blair; H Cittone; E B Clark; M D Cotton; T R Utterback; H Khouri; H Qin; J Vamathevan; J Gill; V Scarlato; V Masignani; M Pizza; G Grandi; L Sun; H O Smith; C M Fraser; E R Moxon; R Rappuoli; J C Venter
Journal:  Science       Date:  2000-03-10       Impact factor: 47.728

6.  Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays.

Authors:  Renata Grifantini; Erika Bartolini; Alessandro Muzzi; Monia Draghi; Elisabetta Frigimelica; Joel Berger; Giulio Ratti; Roberto Petracca; Giuliano Galli; Mauro Agnusdei; Marzia Monica Giuliani; Laura Santini; Brunella Brunelli; Hervé Tettelin; Rino Rappuoli; Filippo Randazzo; Guido Grandi
Journal:  Nat Biotechnol       Date:  2002-08-12       Impact factor: 54.908

7.  Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine.

Authors:  Jo Anne Welsch; Raffaella Rossi; Maurizio Comanducci; Dan M Granoff
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

8.  Vaccine potential of the Neisseria meningitidis 2086 lipoprotein.

Authors:  Leah D Fletcher; Liesel Bernfield; Vicki Barniak; John E Farley; Alan Howell; Melissa Knauf; Peggy Ooi; Robert P Smith; Paige Weise; Mike Wetherell; Xiaoling Xie; Robert Zagursky; Ying Zhang; Gary W Zlotnick
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

9.  Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870.

Authors:  Vega Masignani; Maurizio Comanducci; Marzia Monica Giuliani; Stefania Bambini; Jeannette Adu-Bobie; Beatrice Arico; Brunella Brunelli; Alessandro Pieri; Laura Santini; Silvana Savino; Davide Serruto; David Litt; Simon Kroll; Jo Anne Welsch; Dan M Granoff; Rino Rappuoli; Mariagrazia Pizza
Journal:  J Exp Med       Date:  2003-03-17       Impact factor: 14.307

10.  MUSCLE: a multiple sequence alignment method with reduced time and space complexity.

Authors:  Robert C Edgar
Journal:  BMC Bioinformatics       Date:  2004-08-19       Impact factor: 3.169

View more
  41 in total

1.  Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood.

Authors:  Kathleen Y Dunphy; Peter T Beernink; Barbara Brogioni; Dan M Granoff
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

2.  A meningococcal vaccine antigen engineered to increase thermal stability and stabilize protective epitopes.

Authors:  Monica Konar; Rolando Pajon; Peter T Beernink
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-16       Impact factor: 11.205

3.  Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined.

Authors:  Massimiliano Biagini; Marco Spinsanti; Gabriella De Angelis; Sara Tomei; Ilaria Ferlenghi; Maria Scarselli; Fabio Rigat; Nicola Messuti; Alessia Biolchi; Alessandro Muzzi; Giulia Anderloni; Brunella Brunelli; Elena Cartocci; Francesca Buricchi; Chiara Tani; Maria Stella; Monica Moschioni; Elena Del Tordello; Annalisa Colaprico; Silvana Savino; Marzia M Giuliani; Isabel Delany; Mariagrazia Pizza; Paolo Costantino; Nathalie Norais; Rino Rappuoli; Vega Masignani
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-17       Impact factor: 11.205

4.  Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein.

Authors:  Serena Giuntini; Donald C Reason; Dan M Granoff
Journal:  Infect Immun       Date:  2011-11-07       Impact factor: 3.441

5.  Neisseria meningitidis disease-associated clones in Amazonas State, Brazil.

Authors:  Luciete A Silva; Beatriz Coronato; Jessica Schlackman; Jane W Marsh; Chinelo Ezeonwuka; Andréia C L Fernandes; Victor C Souza; Lirna S da Silva; Elaine F Q de Amorim; Felipe G Naveca; Bernardino C de Albuquerque; Alcirene Amaral; Ana L S Souza; Filipe A Carvalho-Costa; Mustapha M Mustapha; Lee H Harrison; David E Barroso
Journal:  Infect Dis (Lond)       Date:  2018-04-06

6.  A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines.

Authors:  Oliver Koeberling; Isabel Delany; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

7.  Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci.

Authors:  Serena Giuntini; Eduardo Lujan; Malick M Gibani; Christina Dold; Christine S Rollier; Andrew J Pollard; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

8.  Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys.

Authors:  Oliver Koeberling; Anja Seubert; George Santos; Annalisa Colaprico; Mildred Ugozzoli; John Donnelly; Dan M Granoff
Journal:  Vaccine       Date:  2011-05-13       Impact factor: 3.641

9.  Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates.

Authors:  Jane W Marsh; Kathleen A Shutt; Rolando Pajon; Mary M Tulenko; Stephen Liu; Rosemary A Hollick; Julia A Kiehlbauch; Thomas A Clark; David S Stephens; Kathryn E Arnold; Robert A Myers; Leonard W Mayer; Lee H Harrison
Journal:  Vaccine       Date:  2011-06-24       Impact factor: 3.641

10.  Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines.

Authors:  Monica Konar; Dan M Granoff; Peter T Beernink
Journal:  J Infect Dis       Date:  2013-05-28       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.